Cancer Biopsy Market Size Worth $92.09 Billion By 2032 | CAGR: 14.8%
The global cancer biopsy market size is expected to reach USD 92.09 billion by 2032, according to a new study by Polaris Market Research. The report “Cancer Biopsy Market Share, Size, Trends, Industry Analysis Report, By Type (Liquid, Biopsy, Tissue Biopsy, and Others); By Product Type; By Application; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
A biopsy is a medical procedure that involves extracting tissue from any part of the body to detect diseases. Different methods, including needle-based or surgical extraction, are used. Imaging tests such as MRIs and CT scans can identify abnormalities, but they cannot differentiate between cancerous and non-cancerous cells. Therefore, biopsies are essential to confirm malignancy diagnoses and involve detailed cellular analysis.
Advancements in liquid biopsies have significantly influenced the growth of the cancer biopsy market. This innovative technique analyzes genetic material in the bloodstream, making it possible to detect and monitor specific cancer types in a non-invasive approach.
Biopsies offer crucial insights into the biology of different cancer types. This information is instrumental in identifying potential drug targets and designing clinical trials to evaluate new therapies. Biopsies are also used to monitor treatment response and identify mechanisms of resistance, contributing to the development of more effective drugs and combination therapies.
What is the Impact of AI on the Cancer Biopsy Market?
The integration of artificial intelligence is transforming the global cancer biopsy market. AI use enhances speed, accuracy, and data integration. Key players are adopting AI-based tools and techniques for precision oncology and innovations in clinical research.
|
AI Application Area |
Impact and Benefits |
|
AI-Enhanced Imaging Analysis |
AI tools improve the detection and characterization of tumors in CT, MRIs, and mammograms. It reduces the risk of false negatives and improves early diagnosis. |
|
Digital Pathology & Slide Analysis |
AI-enabled systems analyze digitized biopsy slides to enable faster, more consistent identification of cancer cells and subtypes. It reduces variability. |
|
AI-Driven Genomic Data Interpretation |
Machine learning (ML) analyzes genomic and molecular data from biopsies. It is used to identify actionable mutations and predict treatment responses. |
|
Clinical Decision Support |
AI integrates multi-modal data from imaging, pathology, and genomics. It assists clinicians in diagnosis, prognosis, and personalized treatment strategies. |
|
Workflow Automation |
Automates routine tasks such as image segmentation and cell counting. It improves lab throughput and diagnostic efficiency. |
The cancer biopsy market is facing numerous challenges. Advanced biopsy techniques and molecular profiling technologies are not readily available in areas with limited resources. Additionally, interpreting complex genomic data requires specialized expertise, which highlights the need for ongoing education and training in oncology. Invasive biopsy procedures can cause discomfort to patients, leading to reluctance to undergo the process. Moreover, the cost of biopsy procedures and related technologies can be too high for some individuals and healthcare systems. It is vital to overcome these challenges to ensure equal access to high-quality biopsy services and to maximize their impact on cancer diagnosis and treatment.
Cancer Biopsy Market Report Highlights
- The liquid biopsy segment is expected to grow at the highest CAGR during the projected period on account of wide usage
- The kits and consumables segment accounted for the largest market share in 2022, which is mainly driven by cost-effectiveness and higher performance.
- The breast cancer segment held a significant market revenue share in 2022, mainly due to its high prevalence rate
- North America region dominated the market with a majority share in 2022, owing to exponential growth in the technology and advanced healthcare system
- The global key market players include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc
Request a free sample copy or read the full market insights: Cancer Biopsy Market
Polaris Market Research has segmented the cancer biopsy market report based on type, product type, application, and region:
Cancer Biopsy, Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Liquid, Biopsy
- Tissue Biopsy
- Others
Cancer Biopsy, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Kits and Consumables
- Instruments
- Services
Cancer Biopsy, Application Outlook (Revenue - USD Billion, 2019 - 2032)
- Breast Cancer
- Cervical Cancer
- Lung Cancer
- Colorectal Cancer
- Others
Cancer Biopsy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Cancer Biopsy Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 30.42 billion |
|
Revenue forecast in 2032 |
USD 92.09 billion |
|
CAGR |
14.8% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
By Type, By Product Type, By Application, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
|
For Specific Research Requirements |
